Merck Sharp & Dohme 8-K Merck Reports Third-Quarter 2008 Financial Results

Exhibit 99.2

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

THIRD QUARTER

2008

EQUITY INCOME FROM AFFILIATES (millions of dollars)

	3Q ‘08		3Q ‘07		YTD 2008		YTD 2007
MERCK / SCHERING-PLOUGH	$	400.2	$	480.9	$	1,158.2	$	1,293.1
ASTRAZENECA LP		139.1		181.2		331.6		608.3
Other (1)		126.3		106.4		350.9		278.8
TOTAL	$	665.6	$	768.5	$	1,840.7	$	2,180.2

⁽¹⁾ Primarily reflects results for Merial Limited, Sanofi Pasteur-MSD and Johnson & JohnsonºMerck Consumer Pharmaceuticals.

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a “NET” basis.

Merial	3Q ‘08		3Q ‘07		YTD 2008		YTD 2007
FRONTLINE, other fipronil	$	253.3	$	241.7	$	901.0	$	866.1
BIOLOGICALS		198.0		162.0		580.9		472.8
IVOMEC, HEARTGARD, other avermectins		128.6		112.8		415.0		366.7
Other Animal Health		72.1		66.7		220.8		192.0
TOTAL MERIAL SALES	$	652.0	$	583.2	$	2,117.7	$	1,897.6
Sanofi Pasteur-MSD	3Q ‘08		3Q ‘07		YTD 2008		YTD 2007
GARDASIL	$	220.1	$	137.0	$	694.1	$	245.0
VIRAL VACCINES		28.9		20.7		80.7		65.0
HEPATITIS VACCINES		19.3		18.0		56.7		53.9
Other Vaccines		298.5		263.6		576.7		535.0
TOTAL SANOFI PASTEUR-MSD SALES	$	566.8	$	439.3	$	1,408.2	$	898.9
Merck / Schering-Plough Collaboration	3Q ‘08		3Q ‘07		YTD 2008		YTD 2007
VYTORIN	$	567.2	$	693.0	$	1,810.5	$	2,003.2
ZETIA		534.3		607.0		1,676.4		1,728.5
TOTAL MERCK / SCHERING-PLOUGH SALES	$	1,101.5	$	1,300.0	$	3,486.9	$	3,731.7

OTHER (INCOME) EXPENSE, NET (millions of dollars)

	3Q ‘08			3Q ‘07			YTD 2008			YTD 2007
INTEREST INCOME	$	(171.3	)	$	(186.9	)	$	(484.2	)	$	(540.9	)
INTEREST EXPENSE		71.4			91.5			194.6			297.2
EXCHANGE LOSSES (GAINS)		52.3			(8.3	)		73.6			(39.8	)
MINORITY INTERESTS		31.2			30.6			93.9			92.0
Other, net(1)		78.2			(107.8	)		(2,075.3	)		(329.7	)
TOTAL	$	61.8		$	(180.9	)	$	(2,197.4	)	$	(521.2	)

⁽¹⁾ Other, net for the first nine months of 2008 primarily reflects a gain of $2.2 billion related to a distribution from AstraZeneca LP.

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

THIRD QUARTER

2008

NET PRODUCT SALES DETAIL (millions of dollars)

	3Q ‘08 vs. 3Q ‘07
PRODUCT	TOTAL % CHG			TOTAL $	U.S. % CHG			U.S. $	Foreign % CHG		Foreign $
COZAAR / HYZAAR		9	%	888		4	%	314	12	%	574
FOSAMAX		-51	%	354		-80	%	96	1	%	258
SINGULAIR		1	%	1,029		-4	%	692	12	%	337
Vaccines:
GARDASIL		-4	%	401		-16	%	276	37	%	125
ROTATEQ		-21	%	134		-23	%	125	-4	%	10
ZOSTAVAX		-82	%	11		-82	%	11	N/A		—
OTHER VIRAL VACCINES(1)		—		430		-2	%	404	66	%	27
HEPATITIS VACCINES(2)		-47	%	36		-56	%	25	-2	%	11
OTHER VACCINES(3)		-17	%	81		-40	%	47	86	%	34
Other Reported Products:
ARCOXIA		27	%	97		N/A		—	27	%	97
CANCIDAS		9	%	148		-30	%	24	23	%	124
COSOPT / TRUSOPT		6	%	209		—		86	11	%	123
CRIXIVAN / STOCRIN		-5	%	69		-33	%	3	-3	%	65
EMEND		40	%	68		33	%	44	53	%	24
INVANZ		43	%	71		38	%	37	50	%	34
ISENTRESS		*		107		*		57	*		51
JANUVIA		*		379		74	%	297	*		82
JANUMET		*		101		*		86	*		14
MAXALT		9	%	136		8	%	93	11	%	43
PRIMAXIN		1	%	188		-32	%	32	12	%	155
PROPECIA		9	%	108		2	%	39	13	%	69
PROSCAR		-10	%	81		-57	%	3	-5	%	77
TIMOPTIC / TIMOPTIC XE		5	%	30		—		2	6	%	28
VASOTEC / VASERETIC		-31	%	82		N/A		—	-31	%	82
ZOCOR		-28	%	157		-69	%	17	-14	%	140
ZOLINZA		32	%	4		29	%	4	N/A		—

* 100% or over

N/A – Not Applicable

⁽¹⁾ – Includes ProQuad, M-M-R II and Varivax.

⁽²⁾ – Includes Recombivax and Vaqta.

⁽³⁾ – Includes Pneumovax, Comvax and Pedvaxhib.

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	3Q ‘08		% CHG		VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	$	5,944	-2	%	-6	—	4
U.S. ($ MM)		3,337	-11	%	-14	3	N/A
Foreign ($ MM)		2,607	13	%	6	-3	10

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

SEPTEMBER YEAR-TO-DATE

2008

NET PRODUCT SALES DETAIL (millions of dollars)

	SEPTEMBER YTD ‘08 vs. SEPTEMBER YTD ‘07
PRODUCT	TOTAL % CHG		TOTAL $	U.S. % CHG		U.S. $	Foreign % CHG		Foreign $
COZAAR / HYZAAR	9	%	2,676	2	%	928	13	%	1,748
FOSAMAX	-45	%	1,235	-71	%	422	3	%	813
SINGULAIR	3	%	3,215	-4	%	2,116	20	%	1,098
Vaccines:
GARDASIL	-2	%	1,117	-11	%	824	36	%	293
ROTATEQ	34	%	502	32	%	470	77	%	32
ZOSTAVAX	—		151	—		151	N/A		—
OTHER VIRAL VACCINES(1)	-4	%	974	-7	%	896	49	%	77
HEPATITIS VACCINES(2)	-51	%	108	-57	%	79	-15	%	29
OTHER VACCINES(3)	-22	%	223	-49	%	109	59	%	113
Other Reported Products:
ARCOXIA	20	%	294	N/A		—	20	%	294
CANCIDAS	13	%	457	-25	%	80	27	%	378
COSOPT / TRUSOPT	9	%	627	—		254	16	%	374
CRIXIVAN / STOCRIN	-3	%	223	-36	%	10	-1	%	213
EMEND	35	%	193	24	%	125	60	%	69
INVANZ	43	%	197	31	%	99	58	%	98
ISENTRESS	*		231	*		131	*		100
JANUVIA	*		984	*		786	*		198
JANUMET	*		232	*		209	*		23
MAXALT	14	%	388	12	%	257	17	%	131
PRIMAXIN	4	%	592	-22	%	124	14	%	467
PROPECIA	9	%	321	—		113	15	%	207
PROSCAR	-23	%	252	-82	%	10	-12	%	242
TIMOPTIC / TIMOPTIC XE	3	%	91	-10	%	5	4	%	85
VASOTEC / VASERETIC	-26	%	271	N/A		—	-26	%	271
ZOCOR	-22	%	513	-49	%	64	-15	%	449
ZOLINZA	32	%	11	25	%	10	*		1

* 100% or over

N/A – Not Applicable

⁽¹⁾ – Includes ProQuad, M-M-R II and Varivax.

⁽²⁾ – Includes Recombivax and Vaqta.

⁽³⁾ – Includes Pneumovax, Comvax and Pedvaxhib.

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	SEP YTD ‘08		% CHG		VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	$	17,818	-1	%	-4	-1	4
U.S. ($ MM)		9,974	-9	%	-10	1	N/A
Foreign ($ MM)		7,844	12	%	6	-4	11